SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-052434
Filing Date
2024-06-13
Accepted
2024-06-13 16:01:28
Documents
3
Period of Report
2024-06-13

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0207636-6k_clearmind.htm 6-K 11234
2 PRESS RELEASE TITLED: "CLEARMIND MEDICINE REVOLUTIONIZES THE $13 BILLION NONALCO ea020763602ex99-1_clearmind.htm EX-99.1 9406
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12669
  Complete submission text file 0001213900-24-052434.txt   39297
Mailing Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5
Business Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5 972-54-5704749
Clearmind Medicine Inc. (Filer) CIK: 0001892500 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 6-K | Act: 34 | File No.: 001-41557 | Film No.: 241041168
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)